Seminar Series Archive

January 9

• Chuan Wu, M.D., Ph.D., Stadman Investigator, Experimental Immunology Branch, “Gut-liver axis calibrates intestinal stem cell fitness”
• Jennifer Kanakry, M.D., Senior Clinician, NIH Hematology Oncology Fellowship, “Graft versus Tumor Effect in Allogeneic Hematopoietic Cell Transplantation”

February 6

• Natalie Porat-Shliom, Ph.D., Stadtman Investigator, Thoracic and GI Malignancies Branch, “A Spatial Map of Hepatic Mitochondria Uncovers Functional Heterogeneity Shaped by Nutrient-Sensing Signaling”
• James N. Kochenderfer, M.D.,Senior Investigator, Surgery Branch, “Adoptive T-cell Therapies for Hematologic Malignancies”

March 5

• Michail Lionakis, M.D., Sc.D. Chief, Fungal Pathogenesis Section, NIAID. “AIRE deficiency: A treatable IFN-?-opathy”
• Chen Zhao, M.D., Stadtman Investigator, Thoracic and GI Malignancies Branch, “Targeting intratumor bacteria to overcome immunotherapy resistance in NSCLC”

April 2

• Christine Heske, M.D., Investigator, Head, Translational Sarcoma Biology Section, Pediatric Oncology Branch, CCR. “Targeting DNA damage repair in immunologically “cold” pediatric sarcoma”
• Vid Leko, M.D., Physician-Scientist Early Investigator, Myeloid Malignancies Program “Diversifying Cancer Neoantigen Targets for T Cell-Based Immunotherapy”

May 7

• Amiran Dzutsev, Ph.D, M.D., Stadtman Investigator, Laboratory of Integrative Cancer Immunology, “Integrating Microbiome into the Cancer Immunotherapy Equation”
• Jonathan Hernandez, M.D., Investigator, Surgical Oncology Program, “Liver Colonization: From the Operating Room to the Mouse to the Ex Vivo Liver”

June 11

• Kylynda Bauer, Ph.D., Postdoctoral Fellow Greten Laboratory, Thoracic and GI Malignancies Branch, “Gut Microbes Influence Neuroimmune Interactions in Liver Cancer”
• Christian Mayer Ph.D., Stadtman Tenure-Track Investigator, Experimental Immunology Branch, “Limited clonal deletion during B lymphocyte development”

January 10

• Claudia Kemper, Ph.D., Senior Investigator, NHLBI, Laboratory for Complement and Inflammation Research. “New tricks for a very old dog: the complosome and cell physiology”
• Nicolas Çuburu, Ph.D., Staff scientist, Laboratory of Cellular Oncology, “Recruitment of Antiviral T Cells to Treat Virus Negative Tumors”

February 7

• Claudia Palena, Ph.D., Senior Investigator, Center for Immuno-Oncology, Head, Tumor Immunoregulation section. “Tumor cell plasticity mechanisms and their impact on cancer immunotherapy”
• James Hodge, Ph.D., M.B.A. Senior Investigator, Center for Immuno-Oncology, Deputy director for translational research, Head, Immunotherapeutics section. “Exploiting Immunogenic Modulation and Immune Conditioning for Combining Cancer Immunotherapy Strategies with Standard-of-Care and Experimental Therapies”

March 7

• Anandani Nellan, PhD., M.P.H., Physician-Scientist Early Investigator, Pediatric Oncology Branch, NIH Distinguished Scholar. “Tumor mediated immunosuppression and CAR-T cell function in high-risk posterior fossa ependymoma”
• Fatima Karzai, MD., Associate Research Physician, Genitourinary Malignancies Branch, Branch Clinical Director. “Immunotherapy in Prostate Cancer: How to Distinguish the Right from the Wrong”

April 11

• George Pavlakis, M.D., Ph.D., NCI Scientist Emeritus, Vaccine Branch, “Clinical Development of heterodimeric IL-15 cytokine for cancer immunotherapy”
• Stephen K. Anderson, Ph.D., Senior Investigator, Cancer Innovation Laboratory, Head Molecular Immunology section. “NK cells to hematopoiesis, how promoter switches program cell fate”

May 2

• Roxanne Tussiwand, Ph.D., Stadtman Investigator, Immune Regulation Unit, NIDCR. “Notch sets the molecular clock for T cell development”
• Yinling Hu, Ph.D., Senior Investigator, Cancer Innovation Laboratory, Head Inflammation and Tumorigenesis section. “Oral Fungal Infection Constitutes Tumor Microenvironment”

June 13

• Eugene Koonin, Ph.D., NIH distinguished Investigator, Evolutionary Genomics Research Group, NLM/NCBI “Antivirus defense systems in prokaryotes: astonishing diversity and emerging trends”
• Mark R. Gilbert, M.D., Chief Neuro-Oncology Branch, CCR Deputy Director, Head, Translational Immunology Research Program. “Tackling the Challenge of Immunotherapy for Glioblastoma: Identifying Predictors of Response (and Failure)”

September 5

• David Milewski, Ph.D., Genetics Branch, “Integrative multi-omics for developing combination immunotherapies against pediatric tumors”
• Ronald Germain, M.D., Ph.D., Chief, Laboratory of Immune System Biology; Director, Center for Advanced Tissue Imaging (CAT-I). “Using Advanced Multiplex Microscopy and Computational Tools to Analyze Immune Responses in the Tumor Microenvironment”

October 3

• Avinash Bhandoola, M.B., B.S., Ph.D., Senior investigator, Laboratory of Genome Integrity; Head, T-Cell Biology and Development Unit; “Tissue-specific metabolic adaptation of type 3 innate lymphocytes in the gut requires transcription factor Tox2”
• Jung-Hyun Park, Ph.D., Senior investigator, Experimental Immunology Branch; “One chain to rule them all: the common ?-chain cytokine receptor in T cell immunity”

November 7

• Sri Krishna,D., Stadtman investigator, Surgery Branch. “What can neoantigen-specific T cells teach us about human antitumor immunity? ”
• Vassiliki Saloura, D., Ph.D., Stadtman investigator, Thoracic and GI Malignancies Branch “Next Generation ImmunoEpigenetics: Targeting SMYD3 in HPV-negative head and neck squamous cell carcinoma”

December 5

• Rémy Bosselut, M.D., Ph.D., Senior investigator, Laboratory of Immune Cell Biology.  “CD4 T cell responses to chronic infection and tumors; few answers, many questions”
• Tiwary Shweta, Ph.D., Research Fellow, Vaccine Branch. “Omega 3 fatty acids enhance the efficacy of dendritic cell-based cancer vaccine in murine tumor models.”

January 4

• Ai Ing Lim, Postdoctoral research fellow, Yasmine Belkaid’s lab, NIAID. “Pre-birth immune education”
• Udo Rudloff, Senior Investigator, Pediatric Oncology Branch, CCR. “Bivalent innate immune checkpoint designs to enhance anti-tumor responses via CD206-TLR2 co-ligation “

February 1

• Stephanie Goff, Associate research physician, Surgery Branch, “Breast cancers are immunogenic: a cohort study of TIL from metastatic tumors”
• Romina Goldszmid, Stadtman Investigator, Lab of Integrative Cancer Immunology, CCR. “Microbiota programs the tumor microenvironment to promote anticancer immunity “

March 1

• Grégoire Altan-Bonnet, PhD, Senior Investigator, Laboratory of Integrative Cancer Immunology, CCR. “Robotic mapping of T cell activation dynamics in high dimension to quantify tumor antigenicity”
• Ken-Ichi Hanada, M.D., Ph.D., Staff Scientist, Surgery Branch, CCR. “A Phenotypic Signature That Identifies Neoantigen-Reactive CD4 and CD8 T cells in Fresh Human Lung Cancers"

April 5

• Jay A. Berzofsky, M.D, Ph.D., Chief, Vaccine Branch. “Nanoparticle mucosal vaccine against COVID-19 to prevent infection and transmission”
• Clint Allen, M.D, Principal investigator, Translational Tumor Immunology Section, NIHBC. “Neoadjuvant immunotherapy as a feasible path forward to improve recurrence free survival in epithelial cancers”,

May 3

• Rosa Nguyen, MD, PhD., Pediatric Oncology Branch. “Immunocytokines for the therapy of neuroblastoma”
• Scott K Durum, PhD., Laboratory of Cancer Immunometabolism. “The IL-7R pathway in acute lymphoblastic leukemia"

June 14

• Christina M. Annunziata, M.D., Ph.D., Senior Investigator, Women Malignancies Branch. “Monocytes and interferons as an intraperitoneal therapy for ovarian cancer”
• Daniel W. McVicar, Ph.D., Senior Investigator, Laboratory of Cancer Immunometabolism. “The peritoneal metabolic niche: A role for TREM2?”

September 6

• Sung-Yun Pai, M.D., Senior Investigator, Immune Deficiency Cellular Therapy Program. “Gene therapy for Wiskott-Aldrich syndrome”
• Luigi D. Notarangelo, M.D., Chief, Laboratory of Clinical Immunology and Microbiology, Chief, Immune Deficiency Genetics Section. “Multi-omics dissection of the immunopathology of RAG deficiency”

October 4

• Genoveffa Franchini, M.D., Senior Investigator, Vaccine Branch. “Monocytes Efferocytosis, Variable Region 2 (V2) Specific ADCC and mucosal NKp44 cells associated with HIV vaccine candidate efficacy”
• Robert Yarchoan, M.D., Chief, HIV and AIDS Malignancy Branch; Senior Investigator, Head, Viral Oncology Section. “KSHV-Induced Inflammatory Disorders: Multicentric Castleman Disease and KICS”

November 1

• Li Yang, Ph.D., Senior Investigator, Head, Tumor Microenvironment and Metastasis, Laboratory of Cancer Biology and Genetics.  “Tumor suppressors: a critical link to the immune microenvironment, implication in immune checkpoint blockade”
• Peter McGuire, M.S., M.B.B.Ch., Investigator, Metabolic Medicine Branch, NHGRI. “Primary mitochondrial oxidative phosphorylation defects lead to perturbations in the human B cell repertoire”

December 6

• Mary Carrington, Ph.D., Senior Investigator, Laboratory of Integrative Cancer Immunology, Head, HLA Immunogenetics section. “Multitasking of genetic polymorphism at the HLA class I locus T”
• Chris Kanakry, M.D., Lasker Clinical Research Scholar, Center for Immuno-Oncology. “Post-transplantation cyclophosphamide: bench to bedside and back again”

January 5

• Jon Ashwell, Chief, Laboratory of Immune Cell Biology. “Tumor cell-generated glucocorticoids as an immune checkpoint”
• Rosie Kaplan, Pediatric Oncology Branch “Myeloid cells as key regulators of metastasis“

February 2

• Steven Rosenberg, Chief, Surgery Branch. ” Adoptive cell therapy for human solid epithelial cancers”
• James Kochenderfer, Surgery Branch. “ Chimeric antigen receptor T-cell therapies for hematologic malignancies“

March 2

• Masashi Watanabe, Experimental Immunology Branch. “B7-CD28 co-stimulation in innate and adaptive alpha beta T cell development”
• Noa Holtzman, Immune Deficiency Cellular Therapy Program. “JAK inhibition in treatment of Chronic Graft-versus-Host Disease"

April 6

• Giorgio Trinchieri, Chief, Laboratory of Integrative Cancer Immunology, CCR. “Targeting the microbiome in cancer immunotherapy”
• Harry Malech, Chief, Genetic Immunotherapy Section, NIAID. “Antibody mediated myeloid conditioning: Overview of the field and early clinical experience”

May 4

• Lakshmi Balagopalan-Bhise, Laboratory of Cellular and Molecular Biology, CCR. “A journey into T cell Activation: Enjoy the CAR ride”
• Raffit Hassan, Chief, Thoracic and GI Malignancies Branch, CCR. “Mesothelin Targeted Cell Therapy for Malignant Mesothelioma"

June 1

• Noriko Sato, Molecular Imaging Branch, CCR. “Rapid depletion of intra-tumoral Tregs leads to immune activation and tumor vessel regression"
• Pete Choyke, Chief, Molecular Imaging Branch, CCR. “Toward antiCD25 Photoimmunotherapy of cancer”

September 15

• Jeffrey Schlom, Chief, Laboratory of Immunology and Tumor Biology, CCR. “Combination Immunotherapy in HPV Associated Malignancies. Part 1 Basic/Translational Studies”
• Julius Strauss, Laboratory of Immunology and Tumor Biology, CCR. “Combination Immunotherapy in HPV Associated Malignancies-Part 2. Clinical Studies”

October 5

• Glenn Merlino, Scientific Director for Basic Research, CCR “Modeling the initiation, progression and treatment of human melanoma in the mouse”.
• James Yang, Senior Investigator, Surgery Branch, CCR. “Targeting Driver Mutations with T-Cells: Concept and Complexity “

November 2

• Mitchell Ho, Deputy Chief, Laboratory of Molecular Biology, CCR. “Glypicans as Solid Tumor Targets for CAR T Cell Therapy”
• Tim Greten, Deputy Chief, Thoracic and GI Malignancies Branch, CCR. “The immune environment in the liver dictates anti-tumor immune responses to liver tumors “

December 7

• Ira Pastan, Chief Emeritus, Laboratory of Molecular Biology, CCR “Highly Active CAR-T cells for Solid Tumor Therapy Containing an Antibody that Binds to a Juxta-membrane Non-shed Region of Mesothelin”
• Robert Kreitman, Head, Clinical Immunotherapy Section, Laboratory Of Molecular Biology, CCR, “Targeting tumor antigens in patients while avoiding anti-drug antibodies, from mesothelin to CD22“

January 21

• Naomi Taylor, Pediatric Oncology Branch, “Metabolic regulation of T cell effector function: Perspectives for anti-tumor immunotherapy”
• Nirali Shah, Pediatric Oncology Branch, “CAR T-cells and HLH: Exploring a Mechanistic Link”

February 18

• Mary Carrington, Laboratory of Integrative Cancer Immunology, “Functional consequences of differential interactions between HLA class I allotypes and the peptide loading complex”
• Jonathan Lyons, Translational Allergic Immunopathology Unit, NIAID, “Dualistic impact of increased germline TPSAB1 copy number on AML risk and survival”

December 8

• Devaiah Ballachanda, Experimental Immunology Branch, “MYC protein stability is negatively regulated by BRD4”
• Jennifer Kanakry, Experimental Transplantation and Immunotherapy Branch, “Augmenting Host Lymphodepletion in the Transplantation of Patients with Malignant and Non-Malignant Disorders of T-cell Proliferation”